Cooley, Goodwin Procter and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Arsenal Biosciences on the transaction. Arsenal Biosciences (ArsenalBio) announced raising $325 million in Series...
You must be a Standard 1 Year member to access this content.
Goodwin advised Human Immunology Biosciences (HI-Bio) on the round. Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs),...
You must be a Standard 1 Year member to access this content.
Goodwin advised bit.bio on the agreement. BlueRock Therapeutics LP, a wholly owned, independently operated subsidiary of Bayer AG, and bit.bio announced a collaboration and option agreement for...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
You must be a Standard 1 Year member to access this content.
